BPT 958
Alternative Names: BPT-958Latest Information Update: 29 Nov 2024
Price :
$50 *
At a glance
- Originator Bright Peak Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunoconjugates; Immunotherapies; Interleukins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 2 replacements; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer